Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects

Abstract

Background: AFN-1252 is a novel inhibitor of FabI, which is essential in Staphylococcus spp. This study evaluated the safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 immediate-release tablets.

Methods: Part I evaluated AFN-1252 as a single 200 mg dose in fed versus fasted subjects. Part II evaluated 200, 300 and 400 mg doses of AFN-1252 administered once-daily for 10 days.

Results: Pharmacokinetics indicated good absorption with a median T_max of 2–3 hours, and a mean t_1/2 of 7–10 hours, for all doses. C_max and AUC responses were non-linear. A high-fat meal reduced AUC_0–t and C_max values by 62% and 48%, respectively, and delayed T_max by 2.5 hours. All adverse events, including possibly drug-related headache and nausea, were mild or moderate.

Conclusions: Multiple ascending doses of AFN-1252 were safe and well tolerated. AFN-1252 has potential for once- or twice-daily dosing in the treatment of staphylococcal infections.

Keywords:

• AFN-1252
• FabI inhibitor
• Pharmacokinetics
• Phase I
• Safety
• Immediate–release
• Multiple dose
• Staphylococcus aureus

View correction statement:

Corrigendum

Acknowledgements

Micron Research assisted in the preparation of the manuscript.